IHS马基特 INFO 深 沪
等待开盘 11-03 09:30:00 美东时间
24.48
+0.050
+0.20%
华盛通- 最 高24.52
- 今 开24.40
- 成交量 1.47万股
- 最 低 24.40
- 昨 收 24.43
- 总市值 8629.20万
- 52周最高 24.72
- 市盈率 静 8.14
- 换手率 0.42%
- 52周最低 17.15
- 委 比 0.00%
- 总股本 352.50万
- 历史最高 24.72
- 量 比 1.31
- 振 幅 0.49%
- 历史最低 17.15
- 每 手 1
- 风险率 1.53%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Metsera Issues Statement in Response to Litigation
NEW YORK, Oct. 31, 2025 /PRNewswire/ -- Metsera, Inc. (NASDAQ: MTSR) ("Metsera" or the "Company") today issued the following statement in response to litigation filed against the Company by ...
11-01 06:24
Lennar Announces Extension of Expiration Date of Exchange Offer
MIAMI, Oct. 31, 2025 /PRNewswire/ -- Lennar Corporation (NYSE: LEN and LEN.B) ("Lennar") announced today that as a result of the ongoing U.S. federal government shutdown, it is extending the...
11-01 04:30
Heidmar Announces Date for the Third Quarter 2025 Results, Conference Call, and Webcast
Heidmar Maritime Holdings Corp. (NASDAQ: HMR) will release its third-quarter 2025 earnings on November 6, 2025, after market close. A conference call and webcast to discuss the results will be held on November 7, 2025, at 8:00 a.m. ET. Participants can join via phone using the provided dial-in numbers or register for the "call me" option. The webcast will be available live and archived on the Company's website at www.heidmar.com. Founded in 1985,...
10-31 20:05
Equifax Announces Participation in November Investor Conferences
ATLANTA, Oct. 31, 2025 /PRNewswire/ -- Equifax® (NYSE: EFX) will participate in two upcoming investor conferences in November. Mark Begor, Chief Executive Officer, and John Gamble, Chief Fin...
10-31 19:45
Dupixent® (dupilumab) Wins Prestigious 2025 Prix Galien USA Best Biotechnology Product Award
<p>Dupixent, developed by Regeneron, has been awarded the 2025 "Best Biotechnology Product" by the Galien Foundation. It is the first and only therapy targeting the IL-4 and IL-13 signaling pathway, key drivers of type 2 inflammation. Dupixent is approved for eight conditions, including atopic dermatitis, asthma, and COPD, and has helped over 1 million patients globally. The therapy's innovative approach redefines understanding of allergic and at...
10-31 11:00
GERDAU S.A. - CONSOLIDATED INFORMATION
SÃO PAULO, Oct. 30, 2025 /PRNewswire/ -- 3Q25 Highlights Adjusted EBITDA (earnings before interest, taxes, depreciation and amortization) of R$2.7 billion in 3Q25, up 7% compared to 2Q25, wi...
10-31 05:53
SR BANCORP, INC. ANNOUNCES QUARTERLY FINANCIAL RESULTS
BOUND BROOK, N.J., Oct. 30, 2025 /PRNewswire/ -- SR Bancorp, Inc. (the "Company") (NASDAQ: SRBK), the holding company for Somerset Regal Bank (the "Bank"), announced net income of $693,000 f...
10-31 04:35
Equifax Introduces Unemployment Claims Power of Attorney Manager
New Solution Powered by the Equifax Cloud™ Designed to Help Simplify and Accelerate the Unemployment Claims Process for Employers ATLANTA, Oct. 30, 2025 /PRNewswire/ -- Equifax® (NYSE:EFX) t...
10-30 19:45
Metsera Receives Unsolicited Proposal from Novo Nordisk
Metsera Declares Novo Nordisk Proposal "Superior" Novo Nordisk Proposal Values Metsera at up to $77.75 per Share, a Total of Approximately $9 Billion Pursuant to Pfizer Merger Agreement, Met...
10-30 19:07
Humacyte Announces Publication of New Data Comparing Symvess™ to Autologous Vein in Extremity Arterial Trauma
Humacyte announced the publication of a study comparing Symvess to autologous vein in treating extremity arterial trauma. Results showed similar short-term outcomes in patency, limb salvage, and infection rates. Symvess achieved comparable primary patency (86.6% vs. 91.8%), secondary patency (91.0% vs. 97.7%), amputation rate (7.5% vs. 8.2%), and death rate (4.5% vs. 4.5%). While autologous vein is the current gold standard, Symvess offers a viab...
10-30 12:00
